Biomarkers, Frailty, and Implementing EV-Pembro in Bladder Cancer Care
As perioperative EV-pembrolizumab moves into routine bladder cancer care, clinicians discuss the practical challenges of patient selection and multidisciplinary...
Watch NowWhat’s Next in Bladder Cancer Treatment?
The panel looks ahead to the future of bladder cancer treatment, discussing how therapies may evolve beyond current EV-pembrolizumab–based strategies. The group...
Read More
Latest Videos
Implementing KEYNOTE-905 & KEYNOTE-B15 in Community Practice
Dr. Petros Grivas starts the discussion on how KEYNOTE-905 and KEYNOTE-B15 may translate into community bladder cancer care. The panel highlights practical barr...
Watch Now
Neoadjuvant Cycles & ctDNA Decisions
The panel discusses emerging bladder cancer data and how the KEYNOTE-B15 results may influence perioperative treatment decisions in muscle-invasive disease. The...
Watch Now
KEYNOTE-B15: EV + Pembrolizumab vs GemCis in MIBC
At ASCO GU 2026, the group discussed results from KEYNOTE-B15, a phase III trial evaluating perioperative enfortumab vedotin plus pembrolizumab versus standard ...
Watch Now